



VisVires New Protein joins latest Nuritas funding round alongside Cultivian Sandbox

Singapore-based VisVires New Protein is delighted to announce its continued support to discovering novel, natural and scientifically proven active ingredients from food to improve and manage human health, by following-on its early investment in Nuritas and participating in their latest US\$20 million Series A funding round led by Cultivian Sandbox Ventures.

"Nuritas' unique platform delivers truly life-changing health benefits and we are very pleased to be involved in its growth – it's a brilliant team and such an exciting technology," said Nick Rosa, Managing Director of Cultivian Sandbox and Co-founder of Sandbox Industries. "We expect Nuritas to quickly emerge as one of the most innovative companies in the world, effecting real change."

This brings the total invested to date to approximately US\$30 million, including early funding from U2's Bono and The Edge, Salesforce CEO Marc Benioff, and renown angel investor Ali Partovi.

Since launching in 2014, Nuritas has grown rapidly with its AI-powered peptide discovery platform, with applications spanning health and wellness, pharmaceuticals, agriculture and dermatology, amongst others, attracting high-profile investors and partners, including the world's largest chemical producer, BASF SE.

"Nuritas' achievements thus far have been nothing short of spectacular, especially for a young company a little over two years old. We are proud to showcase our commitment to addressing the negative issues around food and health alongside Cultivian Sandbox." said Matthieu Vermersch, Founder and Partner of VisVires New Protein. "We remain confident of Nora, Emmet, and their team's ability to continue delivering game-changing ingredients that could solve some of Asia's most challenging health epidemics such as diabetes"

According to the International Diabetes Federation, an estimated 352 million individuals globally are living with pre-diabetes, which is considered an early warning sign for diabetes. China has the greatest number of diabetics in the world with the disease now affecting more than 98 million people or about 10% of the population.

"Bioactive peptides are known to play a role in managing diabetes and many other areas, but the current methods of identifying those that may work is time-consuming, inefficient and expensive," said Emmet Browne, CEO of Nuritas. "Our artificial intelligence platform has already disrupted this antiquated process by targeting, predicting and unlocking peptides that can positively impact conditions like pre-diabetes, while reducing the cost and time needed to find them. We're excited to have Cultivian Sandbox and our earliest investors such as VisVires New Protein, journey with us on our mission to unlock these huge capabilities to improve human and animal health."

VISVIRES NEW PROTEIN MASTER FUND PTE. LTD.

Business Add : 110 Amoy Street, #02-00, Singapore 069930

Registered Office: 1 Marina Boulevard, #28-00,

One Marina Boulevard, Singapore 018989

Tel : +65 6221 6738 ; Fax : +65 6221 6703

Registration number : 201627007M



Nuritas Founder and Chief Scientific Officer Dr. Nora Khaldi stated, "This latest round of funding will not only help us accelerate our route to market, explore new disease areas and grow our already strong team, but it will also push us even further in extracting the great potential of what our technology is capable of creating."

Nuritas uses a proprietary AI and genomics platform to rapidly analyse the billions of molecules and peptides in food to predict and identify how they impact specific health areas, molecular pathways or receptors. When compared to traditional discovery methods, the Nuritas platform has been shown to identify peptides ten times faster and 500 times more accurately, while significantly reducing costs.

About Nuritas

Founded in 2014, Nuritas is revolutionizing the discovery of novel, natural and scientifically proven active ingredients that can manage and improve human health. The company's disruptive computational approach to discovery uses artificial intelligence, deep learning and genomics to rapidly and efficiently predict and then provide access to the most health-benefitting components hidden within food, called peptides.

Nuritas has received global recognition for the impact its innovative technology will have on the future of food and health. This includes winning the overall Innovation Award at the Forbes Reinventing America Summit in 2015, the Nutrition Capital Network Venture competition in October 2016 and support from EU Horizon 2020 in 2016 for a peptide that carries the potential to prevent pre-diabetic patients from developing diabetes.

About VisVires New Protein:

Based in Singapore, VisVires New Protein (VVNP) is the first Venture Fund in Asia exclusively focused on finding disruptive solutions for the global food and feed system. VVNP employs a disciplined investment approach built on identifying existing global problems within the value-chain through active engagement with a strong network of academia and industry experts. The team strives to uncover game-changing solutions and technologies across the world which can be applied to the larger Asia Pacific region.

VISVIRES NEW PROTEIN MASTER FUND PTE. LTD.

Business Add :110 Amoy Street, #02-00, Singapore 069930

Registered Office: 1 Marina Boulevard, #28-00,

One Marina Boulevard, Singapore 018989

Tel : +65 6221 6738 ; Fax : +65 6221 6703

Registration number : 201627007M